• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of the loss-of-function mechanism of mutant SETD2 and its application to immunotherapy for the patients with renal carcinoma

Research Project

Project/Area Number 20K09550
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionOsaka Medical and Pharmaceutical University

Principal Investigator

Inamoto Teruo  大阪医科薬科大学, 医学部, 准教授 (20330087)

Co-Investigator(Kenkyū-buntansha) 東 治人  大阪医科薬科大学, 医学部, 教授 (40231914)
Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2023: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2022: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywords転移性腎癌 / 遺伝子変異 / 機能喪失 / 腫瘍学 / 腎細胞癌 / 免疫療法 / 泌尿器科 / 腎癌 / 免疫治療
Outline of Research at the Start

aRCCに対するICIとして、本邦において抗PD-1抗体ニボルマブが二次治療に、CTLA-4抗体であるイピリムマブとの併用療法がIMDC intermediate/poorリスクのaRCCに対する1次治療に承認され、欧米で抗PD-1抗体であるペンブロリズマブやアベルマブなどのICIが既に臨床で使用されている。BRAFに対する阻害薬の併用で免疫療法の治療効果の向上がメラノーマでは実現されている一方で、腎癌はBRAFの変異がなく、アプローチを変える必要がある。

Outline of Final Research Achievements

Top genes that cause gene mutations at a frequency of 10% or more (VHL; 71.40%, PBRM1; 57.10%, SETD2; 42.90%, KDM5C; 20.00%, TTN; 17.10%, CACNA1I; 17.10%, BAP1; 14.30%, We comprehensively analyzed the ccRCC database of 1744 people (1813 samples) regarding DYNC1I1; 11.40%, MTOR; 11.40%) to assess the impact of genetic variants on the survival of ccRCC patients. SETD2 had the highest impact on patient survival among somatic mutations in renal cancer.

Academic Significance and Societal Importance of the Research Achievements

いずれの腎癌免疫療法も効果が限定的である理由と解決のヒントは不明である。有力な原因遺伝子を同定し、将来、治療感受性を向上できるのであろうか。腎癌の分子病態の全容解析からすでに重要性が判明しているSETD2の免疫療法における役割の解析は直ちに取り組まないといけないもので、その結果は社会に還元できるものと考える。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (9 results)

All 2023 2022 2021 2020

All Journal Article (3 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (6 results) (of which Int'l Joint Research: 2 results,  Invited: 1 results)

  • [Journal Article] Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.2023

    • Author(s)
      Yonese J, Hinata N, Masui S, Nakai Y, Shirotake S, Takeuchi A, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Morishima N, Ito H, Uemura H.
    • Journal Title

      Int J Urol

      Volume: 30 Issue: 9 Pages: 762-771

    • DOI

      10.1111/iju.15206

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.2022

    • Author(s)
      Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H.
    • Journal Title

      Cancers

      Volume: 14 Issue: 22 Pages: 5659-69

    • DOI

      10.3390/cancers14225659

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib.2022

    • Author(s)
      Inamoto T, Azuma H, Adachi M, Okayama Y, Sunaya T,Oya M.
    • Journal Title

      Future Oncol .

      Volume: 18(11) Issue: 11 Pages: 1371-1380

    • DOI

      10.2217/fon-2021-1001

    • Related Report
      2022 Research-status Report 2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] BLOOD PRESSURE LEVELS DEPENDING ON THE DIFFERENCES IN THE LEVELS OF SALT INTAKE IN KIDNEY TRANSPLANT RECIPIENTS2023

    • Author(s)
      Hirano H, Maenosono R,Fujiwara Y, Taniguchi S,Uehara H,Nomi H,Komura K, Ibuki N,Inamoto T, Azuma H.
    • Organizer
      Transplantation Science Symposium
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] The association between outcome and malnutrition score in hemodialysis associated renal cancer patients.2023

    • Author(s)
      Maenosono R, Okabe T, Shinmyo T, Hanamori T, Goji K, Tsujino T, Uehara H, Komura K, Hirano H, Nomi H, Inamoto T, Azuma H.
    • Organizer
      The 3rd International Congress of the Asian Oncology Society
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 今後の進行性尿路上皮癌の治療のトレンドと本邦でのIO治療の立ち位置2022

    • Author(s)
      稲元 輝生、東 治人。
    • Organizer
      第71回泌尿器科学会中部総会
    • Related Report
      2022 Research-status Report
    • Invited
  • [Presentation] RCC複合免疫療法の上乗せ相手を考える2021

    • Author(s)
      稲元輝生
    • Organizer
      腎細胞がん教育セミナー2021~ Immuno Oncology UPDATE ~
    • Related Report
      2021 Research-status Report
  • [Presentation] Nivo+Ipi併用療法によるDurable responseの価値2021

    • Author(s)
      稲元輝生
    • Organizer
      泌尿器腫瘍 I-O Seminar in 豊野
    • Related Report
      2021 Research-status Report
  • [Presentation] 淡明型腎細胞癌において免疫チェックポイント阻害剤の要となるBRAFの役割はあるのか?2020

    • Author(s)
      稲元 輝生、小村 和正、上原 博史、内本 泰三、伊夫貴 直和、能見 勇人、東 治人
    • Organizer
      日本泌尿器科学会中部総会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi